Literature DB >> 4970220

In vivo interaction of endotoxin with a plasma lipoprotein having esterase activity.

R C Skarnes.   

Abstract

Circulating endotoxin was specifically precipitated from plasma samples withdrawn from three different animal species subsequent to parenteral injection of the toxin. Lipoprotein-positive staining and esterase activity were demonstrated on the precipitation lines formed in immunodiffusion, thus establishing the in vivo interaction of endotoxin with a plasma lipoprotein having esterase activity. Evidence was given to show that the intensity of this interaction in circulating plasma increased gradually with time. The concordance of this in vivo inter-action with the in vitro degradation and inactivation of endotoxin by plasma esterases is discussed.

Mesh:

Substances:

Year:  1968        PMID: 4970220      PMCID: PMC315130          DOI: 10.1128/jb.95.6.2031-2034.1968

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  4 in total

1.  [Characterization of cholinesterase and other carboxylic esterases after electrophoresis and immunoelectrophoresis on agar. I. Application to the study of esterases of normal human serum].

Authors:  J URIEL
Journal:  Ann Inst Pasteur (Paris)       Date:  1961-07

2.  The inactivation of endotoxin after interaction with certain proteins of normal serum.

Authors:  R C Skarnes
Journal:  Ann N Y Acad Sci       Date:  1966-06-30       Impact factor: 5.691

3.  Inactivation of endotoxin by a humoral component. II. Interaction of endotoxin with serum and plasma.

Authors:  R C SKARNES; F S ROSEN; M J SHEAR; M LANDY
Journal:  J Exp Med       Date:  1958-11-01       Impact factor: 14.307

4.  Characterization of a Cr51-labeled endotoxin and its identification in plasma and urine after parenteral administration.

Authors:  L CHEDID; R C SKARNES; M PARANT
Journal:  J Exp Med       Date:  1963-04-01       Impact factor: 14.307

  4 in total
  12 in total

1.  Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein.

Authors:  M M Wurfel; E Hailman; S D Wright
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

2.  Role of complement in lethal bacterial lipopolysaccharide-induced hypotensive and coagulative changes.

Authors:  R J Ulevitch; C G Cochrane
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

3.  Endotoxin-inactivating activity in normal and pathological human blood samples.

Authors:  T Obayashi; H Tamura; S Tanaka; M Ohki; S Takahashi; T Kawai
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

4.  Role of spleen in endotoxin poisoning and reticuloendothelial function.

Authors:  M K Agarwal; M Parant; F Parant
Journal:  Br J Exp Pathol       Date:  1972-10

5.  Endotoxin testing revisited.

Authors:  A Sturk; J W ten Cate
Journal:  Eur J Clin Microbiol       Date:  1985-08       Impact factor: 3.267

6.  Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins.

Authors:  W A Flegel; A Wölpl; D N Männel; H Northoff
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

7.  The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum.

Authors:  R J Ulevitch; A R Johnston
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

8.  Neutralization of bacteria- and endotoxin-induced hypotension by lipoprotein-free human serum.

Authors:  A M Abdelnoor; N R Harvie; A G Johnson
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

9.  Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins.

Authors:  R S Munford; C L Hall; J M Dietschy
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

10.  Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS.

Authors:  M M Wurfel; S T Kunitake; H Lichenstein; J P Kane; S D Wright
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.